March 2026

8th International Congress on Controversies in Fibromyalgia Oral Presentations

Phase 3 RESILIENT Study Post Hoc Analysis
March 2026

2026 American Academy of Pain Medicine (AAPM) PainConnect Annual Meeting

January 2026

Non-Opioid Pain Therapeutics Summit, Boston MA / 27-29 Jan 2026

October 2025

American College of Rheumatology Convergence Conference 2025, Chicago: TNX-102 SL, Cyclobenzaprine HCl Sublingual Tablets, Demonstrates Pain Reduction and Favorable Tolerability in Participants With Fibromyalgia

October 2025

World Vaccine Conference 2025, Amsterdam: Safety, Durability and Protection of a Single-Dose TNX-801 Mpox Vaccine

October 2025

61st Annual Congress of the Japan Society for Transplantation

September 2025

PainWeek 2025 — Randomized, double-blind, placebo-controlled confirmatory Phase 3 trial of bedtime sublingual cyclobenzaprine (TNX-102 SL) in fibromyalgia

September 2025

PainWeek 2025 — Sublingual cyclobenzaprine (TNX-102 SL) for fibromyalgia: efficacy and safety in two randomized placebo-controlled trials

September 2025

PainWeek 2025 — TNX-102 SL, cyclobenzaprine HCl sublingual tablets, demonstrates pain reduction and favorable tolerability in patients with fibromyalgia

September 2025

PainWeek 2025 — Steady-state pharmacokinetic properties of a sublingual formulation of cyclobenzaprine (CBP) HCl (TNX-102 SL): comparison to simulations of oral immediate-release CBP